Testing Psychedelics Efficacy On 'Psychiatry's Blind Spot': Latest King's College Trial
A new open-label study Sponsored by King’s College London (KCL) will assess the effects of a single psilocybin dose of 25 milligram on subjects with a diagnosis of the common and disabling Functional Neurological Disorder (FND).
